These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Engineered proteins as specific binding reagents. Binz HK; Plückthun A Curr Opin Biotechnol; 2005 Aug; 16(4):459-69. PubMed ID: 16005204 [TBL] [Abstract][Full Text] [Related]
5. Alternative non-antibody scaffolds for molecular recognition. Skerra A Curr Opin Biotechnol; 2007 Aug; 18(4):295-304. PubMed ID: 17643280 [TBL] [Abstract][Full Text] [Related]
6. Engineered protein scaffolds for molecular recognition. Skerra A J Mol Recognit; 2000; 13(4):167-87. PubMed ID: 10931555 [TBL] [Abstract][Full Text] [Related]
7. A new generation of protein display scaffolds for molecular recognition. Hosse RJ; Rothe A; Power BE Protein Sci; 2006 Jan; 15(1):14-27. PubMed ID: 16373474 [TBL] [Abstract][Full Text] [Related]
8. Phage display for engineering and analyzing protein interaction interfaces. Sidhu SS; Koide S Curr Opin Struct Biol; 2007 Aug; 17(4):481-7. PubMed ID: 17870470 [TBL] [Abstract][Full Text] [Related]
9. Screening for peptide drugs from the natural repertoire of biodiverse protein folds. Watt PM Nat Biotechnol; 2006 Feb; 24(2):177-83. PubMed ID: 16465163 [TBL] [Abstract][Full Text] [Related]
10. Screening libraries to identify proteins with desired binding activities using a split-GFP reassembly assay. Jackrel ME; Cortajarena AL; Liu TY; Regan L ACS Chem Biol; 2010 Jun; 5(6):553-62. PubMed ID: 20038141 [TBL] [Abstract][Full Text] [Related]
12. In vivo selection of intrabodies specifically targeting protein-protein interactions: a general platform for an "undruggable" class of disease targets. Visintin M; Melchionna T; Cannistraci I; Cattaneo A J Biotechnol; 2008 May; 135(1):1-15. PubMed ID: 18395925 [TBL] [Abstract][Full Text] [Related]
13. Anti-idiotypic protein domains selected from protein A-based affibody libraries. Eklund M; Axelsson L; Uhlén M; Nygren PA Proteins; 2002 Aug; 48(3):454-62. PubMed ID: 12112671 [TBL] [Abstract][Full Text] [Related]
14. Molecular evolution of cystine-stabilized miniproteins as stable proteinaceous binders. Chang HJ; Hsu HJ; Chang CF; Peng HP; Sun YK; Yu HM; Shih HC; Song CY; Lin YT; Chen CC; Wang CH; Yang AS Structure; 2009 Apr; 17(4):620-31. PubMed ID: 19368895 [TBL] [Abstract][Full Text] [Related]
15. Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold. Nygren PA FEBS J; 2008 Jun; 275(11):2668-76. PubMed ID: 18435759 [TBL] [Abstract][Full Text] [Related]
16. A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design. Card GL; Blasdel L; England BP; Zhang C; Suzuki Y; Gillette S; Fong D; Ibrahim PN; Artis DR; Bollag G; Milburn MV; Kim SH; Schlessinger J; Zhang KY Nat Biotechnol; 2005 Feb; 23(2):201-7. PubMed ID: 15685167 [TBL] [Abstract][Full Text] [Related]
17. Alternative binding proteins: anticalins - harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities. Skerra A FEBS J; 2008 Jun; 275(11):2677-83. PubMed ID: 18435758 [TBL] [Abstract][Full Text] [Related]
18. Incorporating receptor flexibility in the molecular design of protein interfaces. Li L; Liang S; Pilcher MM; Meroueh SO Protein Eng Des Sel; 2009 Sep; 22(9):575-86. PubMed ID: 19643976 [TBL] [Abstract][Full Text] [Related]
19. Protein-protein interactions and selection: generation of molecule-binding proteins on the basis of tertiary structural information. Umetsu M; Nakanishi T; Asano R; Hattori T; Kumagai I FEBS J; 2010 May; 277(9):2006-14. PubMed ID: 20412054 [TBL] [Abstract][Full Text] [Related]
20. Domains mediate protein-protein interactions and nucleate protein assemblies. Costa S; Cesareni G Handb Exp Pharmacol; 2008; (186):383-405. PubMed ID: 18491061 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]